TrialNeuro-oncology2017

Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Tracy T Batchelor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.